Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Int J Public Health ; 60(4): 487-94, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25850531

RESUMO

OBJECTIVES: To test whether str oke features relate to living standard within one city by comparing 2 districts. METHODS: District-8 (D-8) ranks the last, whereas District-12 (D-12) is the second regarding personal monthly income of the 23 districts of Budapest, Hungary. Stroke cases hospitalized in 2007 were identified by the database of the National Health Insurance Fund and postal codes for living address. Case certification was performed by personal visits to the general practitioners. Demographic data, risk factors and survival status in 2010 were analyzed using the anonymized database. RESULTS: Three-year case fatality was 36.6 % in D-8 and 31.5 % in D-12 (p = 0.24). Of the fatal cases, men were more than 12 years younger in D-8 than in D-12 (69.2 ± 13.3 vs. 82.4 ± 9.2 years, p < 0.001). Men died younger than women in D-8 (69.2 ± 13.3 vs. 75.2 ± 12.4; p = 0.036), but not in D-12 (82.4 ± 9.2 vs. 81.9 ± 7.3, p = 0.8). Non-treated hypertension, alcohol dependence, and smoking were significantly more prevalent in the poor district (p < 0.01 for all). CONCLUSION: In national stroke programs of former Eastern Block countries, primary prevention should focus especially on male populations of less wealthy regions.


Assuntos
Acidente Vascular Cerebral/epidemiologia , Adulto , Distribuição por Idade , Idoso , Idoso de 80 Anos ou mais , Consumo de Bebidas Alcoólicas/epidemiologia , Comorbidade , Feminino , Comportamentos Relacionados com a Saúde , Humanos , Hungria , Masculino , Pessoa de Meia-Idade , Prevalência , Fatores de Risco , Distribuição por Sexo , Fumar/epidemiologia , Fatores Socioeconômicos , Acidente Vascular Cerebral/mortalidade , Análise de Sobrevida
2.
Ideggyogy Sz ; 64(1-2): 29-35, 2011 Jan 30.
Artigo em Húngaro | MEDLINE | ID: mdl-21428036

RESUMO

BACKGROUND: Fabry-disease (FD) is a rare X-linked lysosomal storage disease. Deficiency of alpha-galactosidase A activity leads to the accumulation of neutral glycosphingolipids, primarily globotriaosylceramide (GL-3) in various tissues, particularly blood vessels, kidneys, myocardium and in ganglions of the peripheral and autonomic nervous system and causes diverse symptoms. The classical phenotype is seen in most males and rarely in females. In women, symptoms start later and the severity is milder. Both peripheral and central nervous system can be both affected. OBJECTIVES: Fabry-patiens and gene-carriers in the central region of Hungary are treated in the 2nd Pediatric Department, Semmelweis University. These patients are consulted by an interdisciplinary team. At present, four hemizygous male, four heterozygous female Fabry-patients and three asymptomatic heterozygous gene carriers are followed. RESULTS: After reviewing the neurological complications of FD, we present clinical and neuroimaging data of our patients. CONCLUSION: We emphasize that neurologists should suspect the rare monogenic FD in the case of acroparaesthesia and heat-cold intolerance in childhood or adolescence; clinical signs of TIA/stroke or unexplained MRI alterations suggesting small vessel disease in young adults. Early diagnosis and introduction of enzyme replacement therapy (ERT) can halt or reverse progression.


Assuntos
Doença de Fabry/complicações , Doença de Fabry/diagnóstico , Doenças do Sistema Nervoso/enzimologia , Fatores Etários , Doenças do Sistema Nervoso Central/enzimologia , Progressão da Doença , Terapia de Reposição de Enzimas , Doença de Fabry/enzimologia , Doença de Fabry/genética , Doença de Fabry/metabolismo , Feminino , Heterozigoto , Humanos , Masculino , Doenças do Sistema Nervoso/metabolismo , Glicoesfingolipídeos Neutros/metabolismo , Doenças do Sistema Nervoso Periférico/enzimologia , Fenótipo , Transtornos de Sensação/enzimologia , Índice de Gravidade de Doença , Fatores Sexuais , alfa-Galactosidase/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA